Compare AbCellera Biologics Inc (ABCL) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Delta Air Lines, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Delta Air Lines, Inc. trades at $87.2 (market cap $58.23B). The key difference: Delta Air Lines, Inc. is far larger — about 24.8× AbCellera Biologics Inc's market cap, and Delta Air Lines, Inc. pays a 0.88% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DAL | |
|---|---|---|
Market Cap | $2.35B | $58.23B |
Sector | Health | Industrials |
52-Week High | $8.12 | $93.66 |
52-Week Low | $2.78 | $50.52 |
Enterprise Value | $1.99B | $73.48B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Delta Air Lines (DAL) trades at $88.63, down 4.44% today, but maintains strong fundamentals with consistent earnings beats and improving cash flow. The stock shows bullish technical signals with moving averages supporting upward momentum, while trading near key support at $88. Analysts remain overwhelmingly positive with 81% buy ratings and a $105.36 consensus target, representing 19% upside potential from current levels.
DAL presents a compelling investment case with attractive valuation multiples (P/E 13.38, P/S 0.92) and robust profitability (ROE 24.99%). However, investors face risks from fuel price volatility, labor cost pressures, and cyclical industry exposure. The upcoming Q2 earnings report on July 10 will be critical for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
